Optimistic Buy Rating for IO Biotech Amidst Promising Clinical Trial Progress and Accelerated PFS Data Timeline
Analysts Are Bullish on These Healthcare Stocks: IO Biotech (IOBT), Iterum Therapeutics (ITRM)
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Buy Recommendation for IO Biotech on Strong Data Prospects and Undervalued Stock Position
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.